Cancer of unknown primary site in which tumor marker-oriented chemotherapy was effective and pancreatic cancer was finally confirmed at autopsy

Intern Med. 2009;48(18):1651-6. doi: 10.2169/internalmedicine.48.2432. Epub 2009 Sep 15.

Abstract

We report a 47-year-old man with cancer of unknown primary site in whom pancreatic cancer was confirmed at autopsy. Although a primary lesion was not confirmed, we planned to perform tumor marker-oriented chemotherapy because pancreatic cancer was suspected as the primary lesion based on tumor markers and pathological findings from metastatic lymph node. Neither S-1 nor gemcitabine was effective. However, gemcitabine combined with low-dose cisplatin therapy resulted in a marked decrease in the size of tumors. Microscopic examination at autopsy revealed poorly differentiated adenocarcinoma in the pancreatic head, although a pancreatic mass was not clear macroscopically.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / diagnosis
  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / metabolism
  • Adenocarcinoma / secondary
  • Antigens, Neoplasm / metabolism
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Autopsy
  • Biomarkers, Tumor / metabolism
  • Cisplatin / administration & dosage
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Gemcitabine
  • Humans
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / metabolism
  • Lung Neoplasms / secondary
  • Lymphatic Metastasis
  • Male
  • Middle Aged
  • Neoplasms, Unknown Primary / diagnosis*
  • Neoplasms, Unknown Primary / drug therapy*
  • Neoplasms, Unknown Primary / metabolism
  • Pancreatic Neoplasms / diagnosis*
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / metabolism

Substances

  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • DU-PAN-2 antigen, human
  • pancreatic associated antigen, SPan-1
  • Deoxycytidine
  • Cisplatin
  • Gemcitabine